Literature DB >> 12681970

Submicroscopic deletions at 7q region are associated with recurrent chromosome abnormalities in acute leukemia.

Rosaria Basiricò1, Rosa Pirrotta, Francesco Fabbiano, Salvo Mirto, Lucia Cascio, Maria Pagano, Giuseppe Cammarata, Silvana Magrin, Alessandra Santoro.   

Abstract

BACKGROUND AND OBJECTIVES: Loss of heterozygosity (LOH) on the long arm of chromosome 7 (7q) has been frequently reported in several types of human cancer including hematologic malignancies. Moreover, monosomy of chromosome 7 and 7q deletions have been associated in acute myeloid leukemia (AML) with aggressive disease and poor prognosis. DESIGN AND METHODS: Using a panel of 11 polymorphic microsatellite markers at bands 7q21-q36, we investigated fifty patients (acute myeloid leukemia [AML], n=33 and acute lymphoid leukemia [ALL], n=17) for LOH, a hallmark of possible involvement of tumor suppressor genes. In parallel, the same acute leukemia (AL) cases were studied by conventional cytogenetics.
RESULTS: A total of 48 spots of allelic loss were observed in 16 (32%) out of 50 patients (AML, n=11 and ALL, n=5). Among LOH+ve cases 3 showed chromosome 7 monosomies, whereas no cytogenetically detectable abnormalities were observed in chromosome 7 in the remaining 13. INTERPRETATION AND
CONCLUSIONS: Comparison with karyotypic results indicated that presence of LOH at 7q21-q36 was significantly associated with other chromosomal aberrations. In fact, an altered karyotype was detectable in 87% of LOH+ve and in 52% of LOH(-ve) AL cases (p=0.024). In addition, LOH at 7q was prevalently associated with unfavorable cytogenetic lesions (p=0.013). Our study represents the first report of a significant association between LOH and recurrent chromosomal abnormalities in AL patients suggesting that the 7q21-q36, region may be an unstable area prone to chromosome breakage in patients with an abnormal karyotype.

Entities:  

Mesh:

Year:  2003        PMID: 12681970

Source DB:  PubMed          Journal:  Haematologica        ISSN: 0390-6078            Impact factor:   9.941


  7 in total

1.  Comprehensive prognostic scoring systems could improve the prognosis of adult acute myeloid leukemia patients.

Authors:  Fan Zhou; Fen Zhou; Mengyi Du; Lin Liu; Tao Guo; Linghui Xia; Runming Jin; Yu Hu; Heng Mei
Journal:  Int J Hematol       Date:  2019-08-22       Impact factor: 2.490

2.  Constitutive expression of the AP-1 transcription factors c-jun, junD, junB, and c-fos and the marginal zone B-cell transcription factor Notch2 in splenic marginal zone lymphoma.

Authors:  Gunhild Trøen; Vigdis Nygaard; Tor-Kristian Jenssen; Ida Münster Ikonomou; Anne Tierens; Estella Matutes; Alicja Gruszka-Westwood; Daniel Catovsky; Ola Myklebost; Grete Lauritzsen; Eivind Hovig; Jan Delabie
Journal:  J Mol Diagn       Date:  2004-11       Impact factor: 5.568

3.  Rap1 and its effector KRIT1/CCM1 regulate beta-catenin signaling.

Authors:  Angela J Glading; Mark H Ginsberg
Journal:  Dis Model Mech       Date:  2009-12-09       Impact factor: 5.758

4.  Adrenal crisis in a patient with acute myeloid leukaemia.

Authors:  Wang Li; Ikemefuna Okwuwa; Karla Toledo-Frazzini; Alaaedin Alhomosh
Journal:  BMJ Case Rep       Date:  2013-07-09

5.  Prevalence of Chromosome 7 Abnormalities in Myelodysplastic Syndrome and Acute Myeloid Leukemia: A Single Center Study and Brief Literature Review.

Authors:  Ruchi Gupta; Shivangi Harankhedkar; Khaliqur Rahman; Manish K Singh; Dinesh Chandra; Navkirti Mittal; Anshul Gupta; Soniya Nityanand
Journal:  Indian J Hematol Blood Transfus       Date:  2018-03-05       Impact factor: 0.900

6.  DOCK4 deletion at 7q31.1 in a de novo acute myeloid leukemia with a normal karyotype.

Authors:  Eigil Kjeldsen; Christopher Veigaard
Journal:  Cell Oncol (Dordr)       Date:  2013-08-27       Impact factor: 6.730

7.  Allelic imbalances in radiation-associated acute myeloid leukemia.

Authors:  Sergiy V Klymenko; Jan Smida; Michael J Atkinson; Volodymir G Bebeshko; Michaela Nathrath; Michael Rosemann
Journal:  Genes (Basel)       Date:  2011-05-31       Impact factor: 4.096

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.